Response-oriented sequential therapy with four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
Not Applicable
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000034815
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
plasma cell leukemia, cardiac amyloidosis, POEMS syndrome, grade 2-4 neuropathy, other malignancy within past 3 years, and other serious complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method